4.5 Article

Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort

Journal

HUMAN MUTATION
Volume 36, Issue 12, Pages 1226-1235

Publisher

WILEY
DOI: 10.1002/humu.22908

Keywords

Alzheimer dementia; EOAD; PLD3; next-generation sequencing; rare variants; meta-analysis

Funding

  1. MetLife Foundation for Medical Research Award (USA)
  2. U. S. Army Medical Research and Material Command (USAMRMC) Research Award
  3. Janssen Pharmaceutical Stellar Research Project
  4. Belgian Science Policy Office Interuniversity Attraction Poles program
  5. Alzheimer Research Foundation (SAOFRA)
  6. Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research (VIND)
  7. Flemish Government initiated Methusalem Excellence Program
  8. Research Foundation Flanders (FWO)
  9. University of Antwerp Research Fund
  10. ISCIII, Cofinancia Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Otra manera de hacer Europa [PI11/00234]
  11. Instituto de Salud Carlos III [PI12/01311]
  12. Grant Agency of Ministry of Health and Charles University Project [PRVOUK P26/1/4 (IGA NT12094-5)]
  13. Fundacao para a Ciencia e a Tecnologia [SFRH/BPD/29354/2006]
  14. Ricerca Corrente, Italian Ministry of Health
  15. the Cassa di Risparmio di Pistoia e Pescia [2014.0365]
  16. Cassa di Risparmio di Firenze [2014.0310]
  17. Ministry of Health [RF-2010-2319722]
  18. Swedish Brain Power, Swedish Research Council [521-2010-3134, A031340]
  19. King Gustaf V and Queen Victoria's Foundation of Freemasons
  20. Foundation of Marianne and Marcus Wallenberg
  21. Foundation of Knut and AliceWallenberg
  22. Foundation of Gun and Bertil Stohne
  23. Foundation of Gamla tjanarinnor
  24. Demensfonden Swedish Alzheimer Foundation [462081]
  25. StratNeuro at Karolinska Institute (KI)
  26. Fundação para a Ciência e a Tecnologia [SFRH/BPD/29354/2006] Funding Source: FCT

Ask authors/readers for more resources

Rare variants in the phospholipase D3 gene (PLD3) were associated with increased risk for late-onset Alzheimer disease (LOAD). We identified a missense mutation in PLD3 in whole-genome sequence data of a patient with autopsy confirmed Alzheimer disease (AD) and onset age of 50 years. Subsequently, we sequenced PLD3 in a Belgian early-onset Alzheimer disease (EOAD) patient (N=261) and control (N=319) cohort, as well as in European EOAD patients (N=946) and control individuals (N=1,209) ascertained in different European countries. Overall, we identified 22 rare variants with a minor allele frequency <1%, 20 missense and two splicing mutations. Burden analysis did not provide significant evidence for an enrichment of rare PLD3 variants in EOAD patients in any of the patient/control cohorts. Also, meta-analysis of the PLD3 data, including a published dataset of a German EOAD cohort, was not significant (P=0.43; OR=1.53, 95% CI 0.60-3.31). Consequently, our data do not support a role for PLD3 rare variants in the genetic etiology of EOAD in European EOAD patients. Our data corroborate the negative replication data obtained in LOAD studies and therefore a genetic role of PLD3 in AD remains to be demonstrated. Published 2015 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available